Verastem Inc
0.0 %
-47.49 %
Yet to be announced
Company Overview
Verastem, Inc. is a development-stage biopharmaceutical company focused on developing and commercializing medicines to treat cancer. The company's lead product candidates include avutometinib (VS-6766), a RAF/MEK inhibitor, and defactinib, a FAK inhibitor. These drugs are being developed for the treatment of various types of cancer including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), and other solid tumors.
Revenue Sources
Verastem is a pre-revenue stage biotechnology company primarily focused on developing cancer treatments. The company's revenue is sporadic and mainly comes from collaboration agreements. The company's business model and product pipeline do not include any haram products or services.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $10.0m | $29.41m | - | $1.14m | 0.00% | 3.87% |
As a development-stage company with minimal revenue, we skip the traditional interest ratio calculations. The company does have interest expenses from its financing activities, which is typical for pre-revenue biotech companies funding their research and development. Given the company's pre-revenue status and R&D focus, this does not indicate interest is core to their business model.
Operational Ethics
Based on review of company filings and public information, there is no evidence of significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Login to join the discussion